PHARMACY

Perrigo acquires remaining stake in Cobrek Pharmaceuticals

BY Jason Owen

ALLEGAN, Mich. — Solidifying Perrigo’s leadership position in topical foam-based generic prescription pharmaceuticals, the company announced it has signed a definitive merger agreement and completed the acquisition of Cobrek Pharmaceuticals, a privately-held, Chicago-based drug development company, for approximately $45 million.

In 2008, Perrigo acquired a minority 18.5% stake in Cobrek as part of a product development partnership agreement focusing on foam dosage form generic pharmaceutical products. The partnership was responsible for the successful launches of Evoclin (i.e., clindamycin phosphate) Foam 1% and Extina (i.e., ketoconazole) Foam 2%. This newest agreement gives Perrigo an 81.5% share of Cobrek on a cash- and debt-free basis.

The sale precedes Perrigo’s expected fiscal year 2013 commercial launches of FDA-approved generic versions of Luxiq (i.e., betamethasone valerate) Foam and Olux-E (i.e., clobetasol propionate) Foam 0.5%.

 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

PHARMACY

FDA approves Mylan’s generic Dilantin chewable tablets

BY Rebecca Haughey

 PITTSBURGH — Mylan on Friday announced that its subsidiary, Mylan Pharmaceuticals, has received final approval from the U.S. Food and Drug Administration for its phenytoin chewable tablets USP in the 50 mg strength.

The product is a generic version of Pfizer’s Dilantin Chewable Tablets, which are indicated for the control of generalized tonic-clonic (i.e., grand mal) and complex partial (i.e., psychomotor, temporal lobe) seizures, and prevention and treatment of seizures occurring during or following neurosurgery.

Phenytoin chewable tablets USP 50 mg, had U.S. sales of approximately $16.5 million for the 12 months ending Sept. 30, 2012, according to IMS Health. Mylan is shipping this new product immediately.

Currently, Mylan has 185 Abbreviated New Drug Applications pending FDA approval, representing $80.6 billion in annual sales, according to IMS Health. Thirty-five of these pending ANDAs are potential first-to-file opportunities, representing $21.2 billion in annual brand sales, for the 12 months ending June 30, 2012, according to IMS Health.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

PHARMACY

Mylan generic heart drug suit against FDA dismissed

BY Jason Owen

WASHINGTON — A federal judge in Washington has dismissed a suit against the FDA brought up by Mylan for withholding approval for the company to sell a generic version of Novartis AG’s heart pill, Diovan.

U.S. District Court Judge John D. Bates said in an opinion filed on Dec. 27, that the FDA did not act “capriciously” when it denied Mylan exclusivity to market its version of Diovan. Bates also said Mylan did not show it suffered “irreparable harm” as a result.

“Given Mylan’s status as a leading generic manufacturer and its already large market presence, the potential financial impact on Mylan’s business is too small to support a finding of irreparable harm,” Bates wrote in the 25-page opinion.

Mylan had argued in the lawsuit that Ranbaxy Laboratories, a competitor, had forfeited its right to six-month exclusivity to sell the generic drug by not winning FDA approval. The FDA’s refusal to approve its sale of the drug was arbitrary, capricious and an abuse of discretion, Mylan asserted.

Mylan, based in Canonsburg, Pa., announced a copy of Diovan HCT on Sept. 21. The generic version is a combination of the Novartis drug and hydrochlorothiazide, a diuretic. At the time, Novartis began marketing a branded version of the drug through its generics unit.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES